AstraZeneca clinches FDA nod for first all-oral, time-limited leukemia therapy
AstraZeneca (NASDAQ:AZN) announced on Friday that the U.S. Food and Drug Administration (FDA) has approved its BTK inhibitor, Calquence (acalabrutinib), in combination with venetoclax as the first all-oral, fixed-duration treatment for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).










